These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22990803)

  • 21. Vaccine efficacy, and immunity affecting transmission.
    Targett G
    Parassitologia; 1999 Sep; 41(1-3):433-6. PubMed ID: 10697899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and parasitological studies on immunity to Plasmodium falciparum malaria in children.
    Høgh B
    Scand J Infect Dis Suppl; 1996; 102():1-53. PubMed ID: 9060051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The case for a subunit vaccine against malaria.
    Anders RF
    Trends Parasitol; 2011 Aug; 27(8):330-4. PubMed ID: 21592861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetically engineered parasites: the solution to designing an effective malaria vaccine?
    Fitchett JR; Cooke MK
    Trends Parasitol; 2010 Jul; 26(7):322-3. PubMed ID: 20537954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Perspectives and challenges of malaria vaccine. Why we must do more].
    Leroy O
    Bull Acad Natl Med; 2007 Oct; 191(7):1249-59; discussion 1259-60. PubMed ID: 18447047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laboratory methods for the conduct of experimental malaria challenge of volunteers.
    Davis JR
    Vaccine; 1994 Mar; 12(4):321-7. PubMed ID: 8178554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine.
    Coban C; Horii T; Akira S; Ishii KJ
    Expert Rev Vaccines; 2010 Jul; 9(7):775-84. PubMed ID: 20624050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
    Patarroyo ME; Patarroyo MA
    Acc Chem Res; 2008 Mar; 41(3):377-86. PubMed ID: 18266328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Delay in the Licensing of Protozoal Vaccines: A Comparative History.
    Palatnik-de-Sousa CB; Nico D
    Front Immunol; 2020; 11():204. PubMed ID: 32210953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3.
    Daubersies P; Thomas AW; Millet P; Brahimi K; Langermans JA; Ollomo B; BenMohamed L; Slierendregt B; Eling W; Van Belkum A; Dubreuil G; Meis JF; Guérin-Marchand C; Cayphas S; Cohen J; Gras-Masse H; Druilhe P
    Nat Med; 2000 Nov; 6(11):1258-63. PubMed ID: 11062538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood stage vaccines for Plasmodium falciparum: current status and the way forward.
    Ellis RD; Sagara I; Doumbo O; Wu Y
    Hum Vaccin; 2010 Aug; 6(8):627-34. PubMed ID: 20519960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine-induced immunity to malaria parasites and the need for novel strategies.
    Good MF
    Trends Parasitol; 2005 Jan; 21(1):29-34. PubMed ID: 15639738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective immunity against malaria by 'natural immunization': a question of dose, parasite diversity, or both?
    Borrmann S; Matuschewski K
    Curr Opin Immunol; 2011 Aug; 23(4):500-8. PubMed ID: 21719266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice.
    Aly AS; Downie MJ; Mamoun CB; Kappe SH
    Cell Microbiol; 2010 Jul; 12(7):930-8. PubMed ID: 20088947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview: immunology of malaria and progress in malaria vaccine development.
    Tharavanij S
    Southeast Asian J Trop Med Public Health; 1992 Sep; 23 Suppl 4():71-87. PubMed ID: 1364871
    [No Abstract]   [Full Text] [Related]  

  • 36. Pregnancy-associated malaria: parasite binding, natural immunity and vaccine development.
    Gamain B; Smith JD; Viebig NK; Gysin J; Scherf A
    Int J Parasitol; 2007 Mar; 37(3-4):273-83. PubMed ID: 17224156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction.
    Hermsen CC; de Vlas SJ; van Gemert GJ; Telgt DS; Verhage DF; Sauerwein RW
    Am J Trop Med Hyg; 2004 Aug; 71(2):196-201. PubMed ID: 15306710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
    Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
    Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional genomic technologies applied to the control of the human malaria parasite, Plasmodium falciparum.
    Carucci DJ
    Pharmacogenomics; 2001 May; 2(2):137-42. PubMed ID: 11368752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress toward a malaria vaccine: efficient induction of protective anti-malaria immunity.
    Tsuji M; Rodrigues EG; Nussenzweig S
    Biol Chem; 2001 Apr; 382(4):553-70. PubMed ID: 11405220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.